§ 01 Overview
Overview
The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations.
Byetta approved April 2005 (first GLP-1 agonist). Bydureon approved January 2012. EXSCEL CVOT (N=14,752) showed CV non-inferiority but not superiority. Weight loss typically 2–4 kg. Largely superseded by semaglutide and tirzepatide clinically but remains historically important.
§ 02 Mechanism
Mechanism of action
Synthetic exendin-4, a 39-amino-acid peptide originally isolated from Heloderma suspectum saliva. Shares 53% homology with native GLP-1 but resists DPP-4 degradation, giving a much longer duration of action. Activates GLP-1R for glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay.
- 01First-in-class GLP-1 agonist; the drug that proved the GLP-1 concept
- 02Extended-release (Bydureon) enables weekly dosing
- 0320+ years of clinical safety data
- 04Unique non-human sequence (exendin-4) with intrinsic DPP-4 resistance
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 5 / 10 mcg pen (Byetta); 2 mg ER pen (Bydureon)
- BAC Water
- N/A; pre-filled
- Dose Range
- 5–10 mcg twice daily (Byetta); 2 mg weekly (Bydureon)
- Starting Dose
- 5 mcg twice daily for 1 month, then 10 mcg
- Route
- SubQ
- Timing
- Byetta: within 60 min of AM/PM meals. Bydureon: any day of week
- Frequency
- Twice daily or weekly per formulation
- Cycle
- Continuous use
Storage
Refrigerate unused.
§ 04 Evidence
Evidence & research
Byetta approved April 2005 (first GLP-1 agonist). Bydureon approved January 2012. EXSCEL CVOT (N=14,752) showed CV non-inferiority but not superiority. Weight loss typically 2–4 kg. Largely superseded by semaglutide and tirzepatide clinically but remains historically important.
FDA Status
FDA-approved (Byetta NDA 021773, 2005; Bydureon BLA 022200, 2012).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Results from Exenatide-PD3 sub-study reveal a new way to predict Parkinson’s progression - Cure Parkinson's
Results from Exenatide-PD3 sub-study reveal a new way to predict Parkinson’s progression Cure Parkinson's
byetta once a week - BusinessWorld Online
byetta once a week BusinessWorld Online
glp 1 inhibitors list - BusinessWorld Online
glp 1 inhibitors list BusinessWorld Online
how long have glp1 been on the market - polskieradio.pl
how long have glp1 been on the market polskieradio.pl
Macleods, Amneal Recall Olanzapine, Exenatide Products in US Over Quality Issues - Medical Dialogues
Macleods, Amneal Recall Olanzapine, Exenatide Products in US Over Quality Issues Medical Dialogues
In 1992, Dr John Eng discovered a molecule in Gila monster venom; decades later, his finding helped pave - The Times of India
In 1992, Dr John Eng discovered a molecule in Gila monster venom; decades later, his finding helped pave The Times of India
The Tao of Drucker: Lessons for Drug Developers from GLP-1 - American Enterprise Institute - AEI
The Tao of Drucker: Lessons for Drug Developers from GLP-1 American Enterprise Institute - AEI
GCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Years - The Clinical Trial Vanguard
GCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Years The Clinical Trial Vanguard
§ 07 Sourcing
Sourcing & supply
Regulatory status
FDA-approved
This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea (very common with Byetta)
- 02Injection site nodules (Bydureon)
- 03Hypoglycemia when combined with sulfonylureas or insulin
Contraindications
- 01Severe GI disease or gastroparesis
- 02End-stage renal disease
- 03History of pancreatitis
§ 10 Questions
Exenatide FAQ
- What is Exenatide?
- The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations. Synthetic exendin-4, a 39-amino-acid peptide originally isolated from Heloderma suspectum saliva. Shares 53% homology with native GLP-1 but resists DPP-4 degradation, giving a much longer duration of action. Activates GLP-1R for glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay.
- What is Exenatide used for?
- Reported uses include first-in-class glp-1 agonist; the drug that proved the glp-1 concept, extended-release (bydureon) enables weekly dosing, 20+ years of clinical safety data, and unique non-human sequence (exendin-4) with intrinsic dpp-4 resistance. Evidence strength is rated Established — see the evidence section for detail.
- How is Exenatide dosed?
- Commonly referenced dosing is 5–10 mcg twice daily (Byetta); 2 mg weekly (Bydureon), typically twice daily or weekly per formulation, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute Exenatide?
- For Exenatide, vials commonly come in 5 / 10 mcg pen (Byetta); 2 mg ER pen (Bydureon) and a common reconstitution is N/A; pre-filled. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of Exenatide?
- Commonly reported side effects include nausea (very common with byetta), injection site nodules (bydureon), and hypoglycemia when combined with sulfonylureas or insulin. This list is not exhaustive.
- Is Exenatide legal?
- This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status. FDA status: FDA-approved (Byetta NDA 021773, 2005; Bydureon BLA 022200, 2012)..
§ 11 References
Selected references
- 01
EXSCEL CVOT
PMID: 28881995 (NCT01144338)
- 02
DURATION-1 (weekly)
PMID: 18819705